North America Anti-Rheumatic Drug Market Size, Share, Opportunities, And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Drug Class (Disease-modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, JAK Inhibitor, Others), And By Sales Channel (Prescription, Over-the-counter (OTC)) - Forecasts From 2022 To 2027

Description

North America Anti-Rheumatic Drug Market

North America Anti-Rheumatic Drug Market is anticipated to expand at a high CAGR over the forecast period (2025-2030).

North America Anti-Rheumatic Drug Market Key Highlights

• The North American market, driven by the United States, commanded the largest share of the global rheumatoid arthritis therapeutics market, accounting for 41.68% of the revenue in 2024.
• The widespread introduction of biosimilars for major reference biologics, particularly in the United States, has initiated a significant pricing contraction and volume growth in the Disease-modifying Anti-Rheumatic Drugs (DMARDs) segment.
• Biologic DMARDs and advanced targeted synthetic DMARDs, such as JAK inhibitors (e.g., AbbVie's Skyrizi and Rinvoq), are experiencing substantial double-digit growth, actively offsetting the revenue erosion faced by legacy blockbuster drugs like Humira and Enbrel.
• Prevalence data from governmental health agencies indicates that approximately 1.2% of Canadians aged 16 years and older live with diagnosed rheumatoid arthritis, underscoring a persistent, high-demand patient base across the region.

The North America Anti-Rheumatic Drug Market is undergoing a fundamental structural shift, moving from dominance by a few high-cost originator biologics toward a competitive multi-player landscape defined by targeted synthetic drugs and an influx of biosimilars. This transition is critically affecting revenue streams and patient access, forcing pharmaceutical manufacturers to accelerate innovation in novel mechanisms of action to maintain market leadership. The high prevalence of various rheumatic diseases, coupled with robust healthcare infrastructure and favorable reimbursement frameworks, establishes North America as the most significant market globally, where demand is perpetually high for therapeutics that can achieve disease remission or low disease activity. The strategic imperative for companies now centers on managing patent cliff exposure while successfully launching next-generation products that deliver superior clinical outcomes in a progressively cost-sensitive environment.

North America Anti-Rheumatic Drug Market Analysis

• Growth Drivers

The increasing prevalence of chronic autoimmune conditions acts as the primary growth catalyst. The sheer volume of patients, exemplified by the Centers for Disease Control and Prevention stating that nearly one in every four adults in the U.S., or 58.5 million people, have some form of arthritis, directly mandates a growing need for pharmacological interventions. Advanced diagnostic capabilities and heightened awareness among both clinicians and the aging population facilitate earlier, more accurate detection, which immediately increases the demand for Disease-Modifying Anti-Rheumatic Drugs (DMARDs) that slow disease progression. Furthermore, the development and regulatory approval of targeted synthetic DMARDs, such as JAK inhibitors, provides new, orally administered options for patients who have failed traditional therapies, expanding the addressable patient pool and driving demand for advanced, high-efficacy treatments.

• Challenges and Opportunities

The dominant challenge is the severe price compression resulting from the proliferation of biosimilars targeting blockbuster biologics like adalimumab. This competitive entry mandates lower net selling prices, directly diminishing the reference product's revenue and requiring manufacturers to manage a sharp decline in peak sales. Conversely, this development presents a major opportunity by expanding patient access to effective biologic therapies that were previously prohibitively expensive for many healthcare systems and individuals, thereby increasing overall treatment volume. Innovation in developing new therapeutic classes with novel mechanisms of action, such as Bruton's Tyrosine Kinase (BTK) inhibitors or new selective JAK inhibitors, creates a market opportunity to command premium pricing for products that demonstrate clinical superiority or offer improved safety profiles over existing standards of care.

• Raw Material and Pricing Analysis

The anti-rheumatic drug market is categorized as a physical product market due to the nature of both small-molecule drugs (synthetic) and large-molecule biologics (derived from living systems). Pricing dynamics are polarized: small-molecule DMARDs have largely become generic and operate within a commodity pricing model, influenced by bulk chemical synthesis costs. Biologic DMARDs, conversely, maintain high costs due to complex manufacturing, stringent quality control, and the need for aseptic processing, which utilizes specialized raw materials, including cell culture media components, bioreactor consumables, and purification resins. The supply chain for these specialized, high-purity raw materials often relies on a limited number of specialized global suppliers. Fluctuations in their availability or price can impact manufacturing margins and lead to drug shortage vulnerabilities, though the final drug price in North America is generally more sensitive to payer negotiation strategies and intellectual property status than to marginal raw material input costs.

• Supply Chain Analysis

The North American anti-rheumatic drug supply chain is characterized by a high-value, high-security logistical flow, particularly for biologic drugs that require cold chain management. Key production hubs for biologics are often concentrated in the U.S. and Puerto Rico, necessitating strict temperature control throughout global distribution networks to maintain drug efficacy. Logistical complexities stem from the sensitivity of biologic products to temperature excursions and the requirement for "track and trace" compliance to mitigate counterfeiting. The dependency on a limited number of specialized third-party logistics (3PL) providers and contract manufacturing organizations (CMOs) for sterile fill-finish operations introduces critical dependency points. Furthermore, the shift towards biosimilars, many manufactured in facilities outside North America, increases global supply complexity and regulatory oversight demands to ensure quality consistency across diverse manufacturing origins.

Government Regulations

The regulatory environment critically shapes market entry, pricing, and adoption.

In-Depth Segment Analysis

• By Drug Class: Disease-modifying Anti-Rheumatic Drugs (DMARDs)

The DMARDs segment is the market's value engine, encompassing both traditional small-molecule synthetics and the higher-value biologics and targeted synthetics. The need for DMARDs is propelled by compelling clinical data demonstrating their ability to achieve and maintain remission, thus preventing irreversible joint damage. This paradigm shift from symptomatic treatment to disease modification fundamentally elevates their demand imperative in clinical guidelines. The influx of multiple adalimumab biosimilars in 2023 and 2024 has served as a crucial growth driver at the volume level. Payers are actively incentivizing the utilization of these lower-cost biosimilars, often mandating a step-therapy approach, which accelerates demand for the genericized biologic class while dampening revenue for the originator products. Concurrently, the increasing clinical utility and physician preference for oral, targeted synthetic DMARDs (JAK inhibitors) that offer comparable efficacy to injectables, drives demand within this sub-class, particularly among patients seeking less invasive administration routes. This segment is characterized by rapid substitution patterns where pricing and clinical convenience intersect to redefine demand flow.

• By Type of Disease: Rheumatoid Arthritis

Rheumatoid Arthritis (RA) represents the single largest application segment for anti-rheumatic drugs, providing the primary basis for market growth due to its chronic, progressive, and highly disabling nature. The necessity is intrinsically tied to the high prevalence rate, where approximately 1.5 million adults in the U.S. are affected. The crucial growth driver in RA is the established "treat-to-target" strategy endorsed by rheumatology guidelines, which demands aggressive, early use of DMARDs and biologics to achieve clinical remission as rapidly as possible. This aggressive treatment philosophy ensures a continuous, high-intensity demand for advanced therapeutic options throughout the patient's lifetime. The disease's systemic inflammatory nature necessitates specialized, high-cost therapies that mitigate extra-articular manifestations, such as cardiovascular complications, further amplifying demand for comprehensive, long-term disease management solutions beyond simple pain relief. The requirement is highly inelastic due to the severe, irreversible consequences of untreated or inadequately managed RA.

Competitive Environment and Analysis

The North American Anti-Rheumatic Drug market operates within an intensely competitive landscape, particularly within the Disease-Modifying Anti-Rheumatic Drug (DMARD) segment. Competition is bifurcated: established pharmaceutical giants contest the high-value biologics and targeted synthetic space, while generics and biosimilars manufacturers erode the market share of off-patent reference products. Key competitive dynamics revolve around maintaining a superior clinical profile (efficacy and safety) for newly launched products and securing favorable formulary placement with major pharmacy benefit managers (PBMs) and payers in the US. The expiration of foundational biologic patents, such as for adalimumab and etanercept, has initiated the "biosimilar wars," forcing originator companies to strategically pivot their revenue base toward next-generation assets like IL-23, IL-17, and JAK inhibitors.

• AbbVie Inc.

AbbVie holds a historically significant strategic position based on the market dominance of its flagship immunology asset, Humira (adalimumab). The company's current strategy focuses on a rapid and successful pivot to its next-generation immunology products, Skyrizi (risankizumab, an IL-23 inhibitor) and Rinvoq (upadacitinib, a JAK inhibitor). In the first quarter of 2024, AbbVie reported that U.S. net revenues for Humira decreased by 39.9% due to biosimilar competition. Simultaneously, global net revenues for Skyrizi and Rinvoq increased by 47.6% and 59.3%, respectively, demonstrating the successful acceleration of their new growth drivers to mitigate the Humira patent cliff. The company is strategically positioning Rinvoq as a high-efficacy, convenient oral option across various rheumatology indications to actively counter the biosimilar threat to their legacy biologic portfolio.

• Amgen Inc.

Amgen remains a vital player in the anti-rheumatic market, with a portfolio anchored by Enbrel (etanercept, a TNF inhibitor) and a developing biosimilar presence, including AMJEVITA® (adalimumab-atto). The company's strategic positioning is one of a dual operator: protecting its established originator biologic while actively participating in the growing biosimilar market. In 2024, Amgen reported that full-year sales of Enbrel decreased by 10%, driven primarily by lower net selling price, a direct result of biosimilar competition within the broader class. Concurrently, sales of their Humira biosimilar, AMJEVITA, increased by 22% for the full year 2024, illustrating a transitional strategy to leverage the market shift toward affordable biologic alternatives and maintain relevance across the entire immunology spectrum.

Recent Market Developments

• November 2024: Johnson & Johnson announced that 43 presentations, including an oral plenary session, were featured at the American College of Rheumatology (ACR) 2024 Annual Meeting. The presentations highlighted new data for the investigational asset nipocalimab in Sjögren's Disease (SjD) and new research supporting the efficacy and safety profile of TREMFYA® (guselkumab) in Psoriatic Arthritis (PsA). This commitment to pipeline and portfolio research, sourced directly from the company's news center, demonstrates a strategic focus on expanding the utility and clinical evidence base for next-generation biologics beyond current indications.
• February 2024: AbbVie announced the completion of its acquisition of ImmunoGen. This acquisition, though primarily focused on oncology with the asset Elahere (mirvetuximab soravtansine), is part of AbbVie’s broader strategy to diversify its revenue base and reduce reliance on its immunology portfolio, which is facing intensifying biosimilar competition. The strategic deployment of capital for M&A is a proactive measure by a major anti-rheumatic market participant to secure new, high-growth revenue streams outside of its traditional, patent-exposed core immunology business.

North America Anti-Rheumatic Drug Market Segmentation:

• By Type of Disease
  • Osteoarthritis
  • Rheumatoid Arthritis
  • Gout
  • Lupus
  • Others
• By Drug Class
  • Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • JAK inhibitor
  • Others
• By Sales Channel
  • Prescription
  • Over-The-Counter (OTC)

Companies Profiled

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Market Segmentation

2. RESEARCH METHODOLOGY  
2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY
3.1. Research Highlights

4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.4. Industry Value Chain Analysis

5. NORTH AMERICA ANTI-RHEUMATIC DRUG MARKET ANALYSIS BY TYPE OF DISEASE
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others

6. NORTH AMERICA ANTI-RHEUMATIC DRUG MARKET ANALYSIS BY DRUG CLASS
6.1. Introduction
6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.4. Corticosteroids
6.5. JAK inhibitor
6.6. Others

7. NORTH AMERICA ANTI-RHEUMATIC DRUG MARKET ANALYSIS BY SALES CHANNEL
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)

8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES
9.1. AbbVie Inc.
9.2. Amget Inc. 
9.3. Johnson and Johnson
9.4. Pfizer Inc.
9.5. GlaxoSmithKline plc
9.6. Merck & Co., Inc.
9.7. Eli Lilly and Company
9.8. Novartis AG
9.9. Celgene Corporation (Bristol-Myers Squibb)

LIST OF FIGURES

LIST OF TABLES

Companies Profiled

AbbVie Inc.

Amget Inc.

Johnson and Johnson

Pfizer Inc.

GlaxoSmithKline plc

Merck & Co., Inc.

Eli Lilly and Company

Novartis AG

Celgene Corporation (Bristol-Myers Squibb)

Related Reports